Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.
The regulator's green light for Rhapsido, a first-in-class oral treatment for chronic hives, positions the company to challenge injectable rivals.
All-stock deal aims to create a diversified semiconductor equipment leader, though Axcelis shares dip on the news.
Gene therapy candidate TSHA-102 for Rett syndrome receives key designation, paving the way for an accelerated regulatory pathway.
A multibillion-dollar AI agreement is in limbo as the US Commerce Department scrutinizes the UAE's ties to Beijing, potentially impacting Nvidia's growth.
The company outlined key milestones for its sublingual drug delivery platform, including a planned 2025 FDA submission for its high-dose aspirin.